Factors Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eun Soo | - |
dc.contributor.author | Kim, Kyeong Ok | - |
dc.contributor.author | Jang, Byung Ik | - |
dc.contributor.author | Lee, Chang Kyun | - |
dc.contributor.author | Kim, Hyo Jong | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Kim, You Sun | - |
dc.contributor.author | Eun, Chang Soo | - |
dc.contributor.author | Jung, Sung-Ae | - |
dc.contributor.author | Yang, Suk-Kyun | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Kim, Tae-Oh | - |
dc.contributor.author | Jung, Yunho | - |
dc.contributor.author | Seo, Geom Seog | - |
dc.contributor.author | Yoon, Soon Man | - |
dc.date.accessioned | 2021-08-11T17:44:40Z | - |
dc.date.available | 2021-08-11T17:44:40Z | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9165 | - |
dc.description.abstract | Background/Aims: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. Methods: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. Results: Overall, 189 patients (139 males; mean age, 32.47 +/- 11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was 'doctor's presence' (68.3%, 82/120), and ADA was "easy to use" (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. Conclusions: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor's presence might be the main contributing factor for this decision. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 거트앤리버 발행위원회 | - |
dc.title | Factors Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study) | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5009/gnl15126 | - |
dc.identifier.scopusid | 2-s2.0-84969217881 | - |
dc.identifier.wosid | 000375350000014 | - |
dc.identifier.bibliographicCitation | Gut and Liver, v.10, no.3, pp 391 - 398 | - |
dc.citation.title | Gut and Liver | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 391 | - |
dc.citation.endPage | 398 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | SHARED DECISION-MAKING | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | PARTICIPATION | - |
dc.subject.keywordPlus | MAINTENANCE | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordAuthor | Crohn disease | - |
dc.subject.keywordAuthor | Infliximab | - |
dc.subject.keywordAuthor | Adalimumab | - |
dc.subject.keywordAuthor | Preference | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.